MEF2D

Information MEF2D

Description

This gene is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2012]

Full Name

myocyte enhancer factor 2D

Source NCBI

ReMap Statistics

Datasets
1
Biotypes
1
Peaks
8,187
Non-redundant peaks
8,187

TF Classification

Super Class
NA
Class
NA
Familly
NA
Sub Familly
NA

Source TFClass

External IDs

JASPAR
MA0773
Ensembl
ENSG00000116604
UniProt
Q14814
Genevisible
Q14814
RefSeq
NM_001271629
Aliases
All peaks MEF2D
Download BED file
Non redundant peaks MEF2D
Download BED file
SEQUENCES MEF2D
Download FASTA file
DOWNLOAD All ReMap
Got to catalogue

Datasets Table for MEF2D

Target name Target modification Ecotype/Strain Biotype Biotype modification Source Species Experiment Peaks
MEF2D K-562 ENCODE Homo sapiens ENCSR647ZXA 8,187
Target name Target modification Ecotype/Strain Biotype Biotype modification Source Species Experiment Peaks

ReMap is a database of transcriptional regulators peaks derived from curated ChIP-seq, ChIP-exo, DAP-seq experiments in Human and Thaliana.

You are using the 2020 ReMap (3rd) release.
The ReMap catalogues (2020, 2018, 2015) are under CC BY-NC 4.0 international license, while ReMapEnrich, remap-pipeline under GNU GPLv3 licence.

Inserm TAGC
AMU AMU-MESO

This work was granted access to the HPC resources of Aix-Marseille Université financed by the project Equip@Meso (ANR-10-EQPX-29-01) of the program "Investissements d’Avenir" supervised by the Agence Nationale de la Recherche.